APOE

Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response

J. A. Nastasi-Catanese, Padilla-Gutiérrez, J. R., Valle, Y., Ortega-Gutiérrez, F., Gallegos-Arreola, M. P., and Figuera, L. E., Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response, vol. 12, pp. 4413-4421, 2013.

Oral anticoagulants of the coumarin type have an inconveniently narrow therapeutic window, making their use difficult. In Mexico, genetic variables that participate in the heterogeneity of the therapeutic response remain poorly investigated. With the focus on warfarin, extensive pharmacogenomic studies have been performed, including those on the CYP450 family and APOE.

Subscribe to APOE